Adaptation of human tumor cells to tirapazamine under aerobic conditions. Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity

Biochemical Pharmacology

Volumn 54, Issue 2, 1997, Pages 249-257

  Elwell, James H ^a   Siim, Bronwyn G ^a   Evans, James W ^a   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioreductive drugs; Manganese superoxide dismutase; NADPH cytochrome P450 reductase; Oxidative stress; Tirapazamine

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE;

ADAPTATION; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR CELL;

ADAPTATION, BIOLOGICAL; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL SURVIVAL; DRUG RESISTANCE; GLUTATHIONE REDUCTASE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; SUPEROXIDES; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0030738399     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00171-8     Document Type: Article

References (51)

1. 2 histography. In: Tumor Oxygenation (Eds. Vaupel PW, Kellerer DK and Gunderoth M), pp. 219-232. Gustav Fischer, Stuttgart, 1995.
2. 2 tension measurements. Cancer Res 51: 6098-6102, 1991.
3. Moulder JE and Rockwell S, Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 5: 313-341, 1987.
4. Kennedy KA, Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 2: 181-194, 1987.
5. Sartorelli AC, Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 48: 775-778, 1988.
6. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50, 1993.
7. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ and Hartz WH, Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838, 1988.
8. Nordsmark M, Overgaard M and Overgaard J, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-40, 1996.
9. Denny WA and Wilson WR, Bioreducible mustards: A paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev 12: 135-151, 1993.
10. Workman P and Stratford IJ, The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73-82, 1993.
11. Brown JM and Sum BG, Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 6: 22-36, 1996.
12. Zeman EM, Brown JM, Lemmon MJ, Hirst VK and Lee WW, SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239-1242, 1986.
13. Kim IH and Brown JM, Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29: 493-497, 1994.
14. Durand RE, The influence of microenvironmental factors during cancer therapy. In Vivo 8: 691-702, 1994.
15. Koch CJ, Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53: 3992-3997, 1993.
16. Brown JM and Lemmon MJ, Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745-7749, 1990.
17. Brown JM and Lemmon MJ, Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20: 457-461, 1991.
18. Dorie MJ and Brown JM, Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633-4636, 1993.
19. Dorie MJ and Brown JM, Potentiation of the anticancer effect of cisplatin by the hypoxic cytotoxin tirapazamine. In: Tumor Oxygenation (Eds. Vaupel PW, Kellerer DK and Gunderoth M), pp. 125-135. Gustav Fischer, Stuttgart, 1995.
20. Langmuir VK, Rooker JA, Osen M, Mendonca HL and Laderoute KR, Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54: 2845-2847, 1994.
21. Brown JM, SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163-1170, 1993.
22. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP and Bridson PK, Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40: 440-445, 1991.
23. Walton MI and Workman P, Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39: 1735-1742, 1990.
24. Walton MI, Wolf CR and Workman P, The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmocol 44: 251-259, 1992.
25. Wang J, Biedermann KA, Wolf CR and Brown JM, Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: Enzymatic studies. Br J Cancer 67:321-325, 1993.
26. Cahill A and White INH, Reductive metabolism of 3-amino-1,2,4'benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis 11: 1407-1411, 1990.
27. Wang J, Biedermann KA and Brown JM, Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 52: 4473-4477, 1992.
28. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S and Roemeling RV, Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 29: 379-382, 1994.
29. Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R and Workman P, Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose escalation strategy in a phase I trial. Cancer Chemother Pharmacol, in press.
30. Koch C, A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat Res 97: 434-442, 1984.
31. Spitz DR and Oberley LW, An assay for superoxide dismutase in mammalian tissue homogenates. Anal Biochem 179: 8-18, 1989.
32. Brannan TS, Maker HS and Raes IP, Regional distribution of catalase in the adult brain. J Neurochem 36: 307-309, 1981.
33. Lawrence RA and Burk RF, Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 71: 952-958, 1976.
34. Ray LE and Prescott JM, Isolation and some characteristics of glutathione reductase from rabbit erythrocytes. Proc Soc Exp Biol Med 148: 402-409, 1976.
35. Prochaska HJ, Santamaria AB and Talalay P, Rapid detection of inducers of enzymes that protect against carcinogens. Proc Natl Acad Sci USA 89: 2394-2398, 1992.
36. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL and Stratford IJ, Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug tirapazamine (SR 4233). Br J Cancer 72:1144-1150, 1995.
37. Kelner MJ and Bagnell R, Alteration of endogenous glutathione peroxidase, manganese superoxide dismutase, and glutathione transferase activity in cells transfected with a copper-zinc superoxide dismutase expression vector. Explanation for variations in paraquat resistance. J Biol Chem 265: 10872-10875, 1990.
38. Keohane A, Godden J, Stratford IJ and Adams GE, The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br J Cancer 61: 722-726, 1990.
39. Silva JM and O'Brien PJ, Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br J Cancer 68: 484-491, 1993.
40. Herscher LL, Krishna MC, Cook JA, Coleman CN, Biaglow JE, Tuttle SW, Gonzalez FJ and Mitchell JB, Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Int J Radiat Oncol Biol Phys 30: 879-885, 1994.
41. Ara G, Coleman CN and Teicher BA, SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. Cancer Lett 85: 195-203, 1994.
42. Walton MI, Smith PJ and Workman P, The role of NAD(P)H: Quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3: 199-206, 1991.
43. Siegel D, Gibson NW, Preusch PC and Ross D, Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483-7489, 1990.
44. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C and Roberts JJ, The nitroreductase enzyme in Walker cells that activates 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-l-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Bio chem Pharmacol 37: 4671-4677, 1988.
45. Riley RJ and Workman P, Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem Pharmacol 43: 167-174, 1992.
46. Baker MA, Zeman EM, Hirst VK and Brown JM, Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res 48: 5947-5952, 1988.
47. Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ and Carmichael J, The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int J Radiat Oncol Biol Phys 29: 369-372, 1994.
48. Plumb JA and Workman P, Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56: 134-139, 1994.
49. Barham HM, Patterson A, Chinje EC, Harris AL and Stratford IJ, Sensitivity to tirapazamine (SR 4233) is determined by P450 reductase activity in human breast but not lung cancer cell lines. Br J Cancer 71(Suppl. XXIV): 20, 1995.
50. Plumb JA, Gerritsen M and Workman P, DT-diaphorase protects cells from the hypoxic cytotoxicity of the indoloquinone EO9. Br J Cancer 70: 1136-1143, 1994.
51. Siim BG, van Zijl PL and Brown JM, Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in fitro. Br J Cancer 73: 952-960, 1996.